VENIPHARM announces the approval of its DCP for enoxaparin biosimilar in Europe.

Saint-Cloud – March 6th, 2019 – VENIPHARM SAS announces that the Decentralized Procedure (DCP) conducted in Europe for a biosimilar of enoxaparin was approved. This achievement is the result of a successful co-development with NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL Co. Ltd., one of the worldwide leading heparin manufacturers.
The DCP involved United Kingdom as the Reference Member State (RMS) and Germany, Spain and Sweden as Concerned Member States (CMS). The national phases of the registration process are ongoing and a Repeat Use Procedure (RUP) will include the other European member states.

Enoxaparin is a low molecular heparin largely used to prevent blood clots in people who are hospitalized or at home. VENIPHARM's enoxaparin biosimilar will be distributed in Europe through leading hospital and retail players. This is an important step for VENIPHARM to expand its international presence in the future.

About VENIPHARM SAS
VENIPHARM is a France-based company principally engaged in the research and development, registration and licensing out of pharmaceutical specialties in Europe.

About NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL Co. Ltd.
Nanjing King Friend is a China-based company principally engaged in the research and development, production and sales of heparin- related products.

VENIPHARM Contact information
Name: Edouard MAUGER
Position: General Manager
Tel: +33137110447
E-mail: venipharm@venipharm.com